
Risperdal
Name of Company: Janssen-Cilag Ltd.
Agency which created Ad: Junction 11, UK
Agency submitting: MERGE
Creative/Account Team: Illustrator: Mark Moran, Art Director: John Timney, Copywriter: Richard Rayment
Creative Rationale:
Approved in 1993 for the treatment of schizophrenia, Risperdal was the second atypical antipsychotic to enter the market. By 2004, clinicians had 6 atypicals to choose from, making differentiation difficult.
With the ‘Living Nightmare’ Campaign, UK-based Junction 11 captured the sinister nature of schizophrenia perfectly as an everyday battle patients face to deliver a strong efficacy claim focused on relapse prevention. The creative work not only set Risperdal apart in terms of its efficacy, but also demonstrated a deeper understanding of the disease it was indicated to treat.
Any awards and honors received:
Epica Awards 2004
Epica Awards 2004
Cresta Awards 2005